Focus on Regulus' Pipeline - Analyst Blog
March 11 2014 - 7:00PM
Zacks
Investors in the pharma/biotech space look forward to pipeline
updates from these companies. Their investment decisions are often
based on such updates. Moreover, pharma/biotech companies invest
significantly to develop their pipelines. Successful development
and subsequent commercialization of pipeline candidates would go a
long way in augmenting the top lines of these companies.
Regulus Therapeutics Inc. (RGLS) is no exception
and is working hard to develop its pipeline. In keeping with its
pipeline development efforts, the biopharmaceutical company
initiated the dosing of healthy volunteers in a phase I study on
its hepatitis C virus candidate RG-101. The study is designed to
primarily evaluate the safety and tolerability of the
candidate.
The study will also assess pharmacokinetics, viral load
reduction and any potential impact of an oral direct-acting
antiviral on the pharmacokinetics of RG-101. The company expects to
come out with proof of concept results from the phase I study by
Dec 31, 2014.
Regulus is developing RG-101 as part of its “road to clinic”
strategy. Through the scheme, launched in Feb 2013, Regulus intends
to develop its microRNA therapeutic pipeline in the direction of
the clinic. Apart from RG-101, Regulus has nominated another
microRNA candidate – RG-102 (alport syndrome) for clinical
development.
Alport syndrome is a life threatening orphan disease driven by
genetic mutations. Regulus has an agreement with
Sanofi (SNY) on RG-102. Regulus has agreements
with many other companies to advance its pipeline.
Regulus currently carries a Zacks Rank #3 (Hold). Some
better-ranked biopharma stocks include Alexion
Pharmaceuticals, Inc. (ALXN) and Gilead Sciences,
Inc. (GILD). Both stocks carry a Zacks Rank #1 (Strong
Buy).
ALEXION PHARMA (ALXN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
REGULUS THERAP (RGLS): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jul 2023 to Jul 2024